type	clinical_trial_id	title	last_update_posted	recruitment_status	project.project_id
clinical_trial	NCT01587703	A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers	March 16, 2020	Completed	3R01CA124633-11A1S1
clinical_trial	NCT01587703	A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers	March 16, 2020	Completed	5R01CA176745-09
clinical_trial	NCT01492673	Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma	October 29, 2019	Completed	3R01CA180279-05S1
clinical_trial	NCT00464620	Trial of Dasatinib in Advanced Sarcomas	November 23, 2018	Completed	3R01CA180279-05S1
clinical_trial	NCT01643278	Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic	January 10, 2017	Completed	3R01CA180279-05S1
clinical_trial	NCT02048371	SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes	August 10, 2021	Recruiting	3R01CA180279-05S1
clinical_trial	NCT01331135	Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors (Aflac ST0901)	May 29, 2020	Completed	3R01CA180279-05S1
clinical_trial	NCT01353625	Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.	May 6, 2021	Completed	3R01CA180279-05S1
clinical_trial	NCT01518413	Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors	February 27, 2015	Completed	3R01CA180279-05S1
clinical_trial	NCT01956669	Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors	August 12, 2020	Completed	3R01CA180279-05S1
clinical_trial	NCT01154816	Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia	May 13, 2020	Completed	3R01CA180279-05S1
clinical_trial	NCT02116777	Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies	March 26, 2021	Completed	3R01CA180279-05S1
clinical_trial	NCT01286987	Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors	January 10, 2019	Completed	3R01CA180279-05S1
clinical_trial	NCT01583543	Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma	May 19, 2017	Completed	3R01CA180279-05S1
clinical_trial	NCT01858168	Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma	November 27, 2020	Recruiting	3R01CA180279-05S1
clinical_trial	NCT02044120	ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma	January 12, 2021	Completed	3R01CA180279-05S1
clinical_trial	NCT01154452	Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma	August 15, 2018	Completed	3R01CA180279-05S1
clinical_trial	NCT00743496	A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma	August 17, 2017	Completed	3R01CA180279-05S1
clinical_trial	NCT02107963	A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors	August 17, 2021	Completed	3R01CA180279-05S1
clinical_trial	NCT00445965	Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer	October 29, 2020	Active, not recruiting	3R01CA180279-05S1
clinical_trial	NCT01610570	Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma	March 2, 2018	Terminated	3R01CA180279-05S1
clinical_trial	NCT01610570	Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma	March 2, 2018	Terminated	3R01CA204915-02S1
clinical_trial	NCT01684150	A Phase 1, Open-Label, Dose-Escalation &amp; Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK &amp; PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving	August 4, 2016	Completed	5R01CA176745-09
clinical_trial	NCT02141828	A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene	May 8, 2020	Completed	5R01CA176745-09
clinical_trial	NCT02141828	A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene	May 8, 2020	Completed	3R01CA204396-02S1
clinical_trial	NCT02141828	A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene	May 8, 2020	Completed	1U01CA232486-01
clinical_trial	NCT01987362	A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies	January 5, 2018	Completed	3R01CA124633-11A1S1
clinical_trial	NCT01987362	A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies	January 5, 2018	Completed	5R01CA176745-09
clinical_trial	NCT02259114	A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)	January 26, 2021	Completed	3R01CA124633-11A1S1
clinical_trial	NCT02259114	A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)	January 26, 2021	Completed	5R01CA176745-09
clinical_trial	NCT01713582	A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)	January 26, 2021	Completed	3R01CA124633-11A1S1
clinical_trial	NCT01713582	A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)	January 26, 2021	Completed	5R01CA176745-09
clinical_trial	NCT01713582	A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)	January 26, 2021	Completed	1U54CA224019-01
clinical_trial	NCT02296476	A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)	January 26, 2021	Terminated	3R01CA124633-11A1S1
clinical_trial	NCT02296476	A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)	January 26, 2021	Terminated	5R01CA176745-09
clinical_trial	NCT02158858	A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis	August 25, 2021	Recruiting	3R01CA124633-11A1S1
clinical_trial	NCT02158858	A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis	August 25, 2021	Recruiting	5R01CA176745-09
clinical_trial	NCT02158858	A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis	August 25, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT01897571	Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL	August 18, 2021	Active, not recruiting	5R01CA176745-09
clinical_trial	NCT01897571	Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL	August 18, 2021	Active, not recruiting	3R01CA204396-02S1
clinical_trial	NCT02082977	A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma	February 25, 2020	Terminated	5R01CA176745-09
clinical_trial	NCT02395601	A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas	September 6, 2019	Completed	5R01CA176745-09
clinical_trial	NCT01949883	A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma	September 6, 2019	Completed	5R01CA176745-09
clinical_trial	NCT02157636	A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma	June 7, 2018	Completed	5R01CA176745-09
clinical_trial	NCT02303782	A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)	September 1, 2016	Withdrawn	5R01CA176745-09
clinical_trial	NCT02034123	Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma	December 6, 2019	Terminated	5R01CA176745-09
clinical_trial	NCT02177812	A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)	June 28, 2019	Terminated	5R01CA176745-09
clinical_trial	NCT02261779	Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible (TCP-AML)	July 7, 2015	Unknown	5R01CA176745-09
clinical_trial	NCT02273102	Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA)	July 21, 2020	Completed	5R01CA176745-09
clinical_trial	NCT01943851	A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies	May 19, 2021	Completed	5R01CA176745-09
clinical_trial	NCT01943851	A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies	May 19, 2021	Completed	1U54CA224019-01
clinical_trial	NCT02601937	A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma	September 2, 2021	Active, not recruiting	5R01CA176745-09
clinical_trial	NCT02098538	Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma	April 27, 2021	Active, not recruiting	3R01CA204396-02S1
clinical_trial	NCT02267603	Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer	March 22, 2021	Active, not recruiting	2UM1CA154967-07
clinical_trial	NCT02431260	An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies	June 14, 2019	Terminated	3R01CA124633-11A1S1
clinical_trial	NCT02431260	An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies	June 14, 2019	Terminated	1U54CA224019-01
clinical_trial	NCT02307240	Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors	September 3, 2019	Completed	3R01CA124633-11A1S1
clinical_trial	NCT02427451	Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia	November 6, 2019	Active, not recruiting	3R01CA205967-03S2
clinical_trial	NCT02236195	Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes	September 1, 2017	Completed	3U24CA210999-02S1
clinical_trial	NCT02334527	Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy	November 16, 2018	Terminated	3U24CA210999-02S1
clinical_trial	NCT00831792	TKI258 in Castrate Resistant Prostate Cancer	September 11, 2019	Completed	1U54CA224079-01
clinical_trial	NCT00753688	Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy (PALETTE)	August 22, 2013	Completed	3R01CA180279-05S1
clinical_trial	NCT01920191	Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma	April 20, 2016	Completed	1U01CA224160-01
clinical_trial	NCT02454634	Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas (NOA-16)	November 7, 2018	Completed	1U01CA224160-01
clinical_trial	NCT02794883	Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma	April 5, 2019	Unknown	1U01CA224160-01
clinical_trial	NCT02017717	A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (CheckMate 143)	April 19, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02337491	Pembrolizumab +/- Bevacizumab for Recurrent GBM	December 22, 2020	Completed	1U01CA224160-01
clinical_trial	NCT02337491	Pembrolizumab +/- Bevacizumab for Recurrent GBM	December 22, 2020	Completed	1U01CA224348-01
clinical_trial	NCT02311582	MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas	September 5, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT01952769	Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma	September 13, 2016	Unknown	1U01CA224160-01
clinical_trial	NCT02336165	Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma	July 15, 2021	Completed	1U01CA224160-01
clinical_trial	NCT02336165	Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma	July 15, 2021	Completed	1U01CA224348-01
clinical_trial	NCT02327078	A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)	August 28, 2020	Completed	1U01CA224160-01
clinical_trial	NCT02313272	Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas	August 10, 2021	Completed	1U01CA224160-01
clinical_trial	NCT02335918	A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors	December 9, 2019	Completed	1U01CA224160-01
clinical_trial	NCT02337686	Pembrolizumab in Treating Patients With Recurrent Glioblastoma	January 29, 2020	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02550249	Neoadjuvant Nivolumab in Glioblastoma (Neo-nivo)	April 11, 2017	Completed	1U01CA224160-01
clinical_trial	NCT02529072	Nivolumab With DC Vaccines for Recurrent Brain Tumors (AVERT)	March 26, 2020	Completed	1U01CA224160-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	July 31, 2020	Completed	1U01CA224160-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	July 31, 2020	Completed	1U01CA224348-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	July 31, 2020	Completed	1U01CA224146-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	July 31, 2020	Completed	1U01CA224175-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	July 31, 2020	Completed	1U01CA224193-01
clinical_trial	NCT02617589	An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)	February 3, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02617589	An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)	February 3, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT02617589	An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)	February 3, 2021	Active, not recruiting	1U2CCA233262-01
clinical_trial	NCT02648633	Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma	May 31, 2017	Terminated	1U01CA224160-01
clinical_trial	NCT02658279	Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype	July 22, 2021	Recruiting	1U01CA224160-01
clinical_trial	NCT02658981	Anti-LAG-3 Alone &amp; in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)	September 10, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02667587	An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate548)	September 11, 2020	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02798406	Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)	July 15, 2021	Completed	1U01CA224160-01
clinical_trial	NCT02829723	A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors	July 27, 2021	Recruiting	1U01CA224160-01
clinical_trial	NCT02852655	A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma	October 1, 2020	Recruiting	1U01CA224160-01
clinical_trial	NCT02937844	Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme	October 19, 2016	Unknown	1U01CA224160-01
clinical_trial	NCT02866747	A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma (STERIMGLI)	July 28, 2021	Recruiting	1U01CA224160-01
clinical_trial	NCT02968940	Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma	June 18, 2021	Completed	1U01CA224160-01
clinical_trial	NCT00643097	Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (ACTIVATe)	February 1, 2017	Completed	1U01CA224160-01
clinical_trial	NCT00458601	Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme (ACT III)	January 16, 2018	Completed	1U01CA224160-01
clinical_trial	NCT01480479	Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)	January 16, 2018	Completed	1U01CA224160-01
clinical_trial	NCT01498328	A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (ReACT)	February 17, 2020	Completed	1U01CA224160-01
clinical_trial	NCT01130077	A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas	August 10, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02078648	Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme	January 26, 2018	Completed	1U01CA224160-01
clinical_trial	NCT02149225	GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients	August 7, 2018	Completed	1U01CA224160-01
clinical_trial	NCT02287428	Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM	May 21, 2021	Recruiting	1U01CA224160-01
clinical_trial	NCT02193347	IDH1 Peptide Vaccine for Recurrent Grade II Glioma (RESIST)	March 15, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT00293423	GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma	May 13, 2021	Completed	1U01CA224160-01
clinical_trial	NCT01814813	Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery	August 18, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02546102	Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma	August 13, 2018	Suspended
                  
      <!--	1U01CA224160-01
clinical_trial	NCT00045968	Study of a Drug [DCVax&#174;-L] to Treat Newly Diagnosed GBM Brain Cancer (GBM)	October 14, 2016	Unknown	1U01CA224160-01
clinical_trial	NCT00846456	Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma	October 20, 2015	Completed	1U01CA224160-01
clinical_trial	NCT02049489	A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma	August 13, 2018	Completed	1U01CA224160-01
clinical_trial	NCT00626483	Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia (REGULATe)	March 9, 2021	Completed	1U01CA224160-01
clinical_trial	NCT00639639	Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (ATTAC)	January 26, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02366728	DC Migration Study for Newly-Diagnosed GBM (ELEVATE)	November 7, 2019	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT00345163	A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN) (BRAIN)	May 16, 2017	Completed	1U01CA224160-01
clinical_trial	NCT00612430	Ph II Bevacizumab + Etoposide for Pts w Recurrent MG	August 12, 2013	Completed	1U01CA224160-01
clinical_trial	NCT00595322	Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma	May 23, 2017	Completed	1U01CA224160-01
clinical_trial	NCT01238237	Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA	February 1, 2017	Completed	1U01CA224160-01
clinical_trial	NCT01884740	Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22	April 20, 2021	Recruiting	1U01CA224160-01
clinical_trial	NCT00753246	Nimotuzumab in Adults With Glioblastoma Multiforma	December 3, 2012	Completed	1U01CA224160-01
clinical_trial	NCT02573324	A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)	May 24, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT00730613	Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma	October 9, 2017	Completed	1U01CA224160-01
clinical_trial	NCT02209376	Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma	March 5, 2019	Terminated	1U01CA224160-01
clinical_trial	NCT01109095	CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM (HERT-GBM)	April 25, 2019	Completed	1U01CA224160-01
clinical_trial	NCT01491893	PVSRIPO for Recurrent Glioblastoma (GBM) (PVSRIPO)	January 12, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT01301430	Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. (ParvOryx01)	December 4, 2015	Completed	1U01CA224160-01
clinical_trial	NCT00390299	Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme	January 2, 2020	Completed	1U01CA224160-01
clinical_trial	NCT01174537	New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma	June 11, 2015	Withdrawn	1U01CA224160-01
clinical_trial	NCT01811992	Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma	August 31, 2021	Completed	1U01CA224160-01
clinical_trial	NCT01750918	BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)	April 19, 2021	Completed	1U54CA224068-01
clinical_trial	NCT01719380	Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer	June 23, 2021	Completed	1U54CA224068-01
clinical_trial	NCT03098160	Immunotherapy Study of Evofosfamide in Combination With Ipilimumab	October 30, 2017	Unknown	3R01CA187532-03S1
clinical_trial	NCT00633724	Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer	August 15, 2013	Completed	1U01CA224348-01
clinical_trial	NCT00874588	Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer	August 15, 2013	Completed	1U01CA224348-01
clinical_trial	NCT02562755	Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS)	December 16, 2020	Completed	1U01CA224348-01
clinical_trial	NCT02616185	A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)	March 9, 2021	Completed	1U01CA224348-01
clinical_trial	NCT01218867	CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer	December 10, 2019	Terminated	1U01CA224348-01
clinical_trial	NCT02857920	Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors	September 14, 2020	Completed	1U01CA224348-01
clinical_trial	NCT00678119	Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment	July 15, 2013	Completed	1U01CA224348-01
clinical_trial	NCT01582672	Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)	June 14, 2018	Terminated	1U01CA224348-01
clinical_trial	NCT01454102	Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)	March 5, 2020	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT02410512	A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors	March 1, 2021	Completed	1U01CA224348-01
clinical_trial	NCT02754856	Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery	January 22, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT02496208	Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	September 5, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT01688206	A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	October 5, 2018	Completed	1U01CA224348-01
clinical_trial	NCT02665416	Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors	April 7, 2020	Completed	1U01CA224348-01
clinical_trial	NCT02715531	A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors	July 9, 2021	Completed	1U01CA224348-01
clinical_trial	NCT02942329	Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer	February 26, 2018	Unknown	1U01CA224348-01
clinical_trial	NCT02856425	Trial Of Pembrolizumab And Nintedanib (PEMBIB)	April 7, 2020	Recruiting	1U01CA224348-01
clinical_trial	NCT03081494	Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer	December 11, 2020	Completed	1U01CA224348-01
clinical_trial	NCT01472081	Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)	April 22, 2020	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT02959554	Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control (NIVOSWITCH)	September 8, 2021	Terminated	1U01CA224348-01
clinical_trial	NCT02777710	Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)	September 5, 2021	Completed	1U01CA224348-01
clinical_trial	NCT02777710	Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)	September 5, 2021	Completed	1U01CA224146-01
clinical_trial	NCT02777710	Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)	September 5, 2021	Completed	1U01CA224175-01
clinical_trial	NCT02777710	Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)	September 5, 2021	Completed	1U01CA224193-01
clinical_trial	NCT02471716	Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor (FPA008-002)	August 31, 2021	Completed	1U01CA224348-01
clinical_trial	NCT02141295	A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (McCAVE)	March 25, 2020	Terminated	1U01CA224348-01
clinical_trial	NCT02744287	Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors	April 26, 2021	Recruiting	3R01CA163915-07S1
clinical_trial	NCT02743611	Safety &amp; Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma	April 27, 2020	Active, not recruiting	3R01CA163915-07S1
clinical_trial	NCT01831505	Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents	February 27, 2017	Completed	1U01CA224348-01
clinical_trial	NCT03056599	Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma	February 12, 2021	Recruiting	1U01CA224348-01
clinical_trial	NCT03127631	A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICALPC)	August 28, 2018	Unknown	1U01CA224348-01
clinical_trial	NCT02907021	Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2 (SCHOLAR)	October 9, 2020	Completed	1U01CA224348-01
clinical_trial	NCT02236806	Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab (SAFE)	January 7, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT01904903	Cardiac Safety Study in Patients With HER2 + Breast Cancer (SAFE-HEaRt)	February 2, 2021	Completed	1U01CA224348-01
clinical_trial	NCT03265574	PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma? (PROACT)	July 17, 2020	Recruiting	1U01CA224348-01
clinical_trial	NCT01968200	Prevention of Anthracycline-induced Cardiotoxicity (ICOS-ONE)	August 13, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT01009918	Lisinopril or Coreg CR&#174; in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab	March 30, 2021	Completed	1U01CA224348-01
clinical_trial	NCT01805453	Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma (ASTER)	May 8, 2020	Completed	1U01CA224348-01
clinical_trial	NCT01754909	Mitigation of Radiation Pneumonitis and Fibrosis	October 8, 2019	Completed	1U01CA224348-01
clinical_trial	NCT01880528	Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer	January 2, 2020	Completed	1U01CA224348-01
clinical_trial	NCT00004230	Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation	June 6, 2012	Completed	1U01CA224348-01
clinical_trial	NCT02651415	Phase II Study of Perindopril and Regorafenib in mCRC (PARICCA)	September 12, 2019	Completed	1U01CA224348-01
clinical_trial	NCT01705392	Bevacizumab vs Dacarbazine in Metastatic Melanoma	February 24, 2017	Terminated	1U01CA224348-01
clinical_trial	NCT00410059	BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC	August 2, 2017	Completed	1U54CA224081-01
clinical_trial	NCT00411671	BATTLE Program: Sorafenib in Patients With NSCLC	February 11, 2016	Completed	1U54CA224081-01
clinical_trial	NCT02122913	A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer	May 12, 2021	Completed	1U54CA224079-01
clinical_trial	NCT02637687	A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT)	September 10, 2021	Recruiting	1U54CA224079-01
clinical_trial	NCT02576431	A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE)	September 8, 2021	Recruiting	1U54CA224079-01
clinical_trial	NCT03213704	Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)	September 5, 2021	Recruiting	1U54CA224079-01
clinical_trial	NCT03215511	A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer	September 13, 2021	Active, not recruiting	1U54CA224079-01
clinical_trial	NCT02097810	Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1)	June 9, 2021	Completed	1U54CA224079-01
clinical_trial	NCT02568267	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	August 30, 2021	Recruiting	1U54CA224079-01
clinical_trial	NCT02650401	Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG)	August 17, 2021	Recruiting	1U54CA224079-01
clinical_trial	NCT03093116	A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	February 1, 2021	Recruiting	1U54CA224079-01
clinical_trial	NCT02920996	Merestinib In Non-Small Cell Lung Cancer And Solid Tumors	August 31, 2021	Active, not recruiting	1U54CA224079-01
clinical_trial	NCT02675491	Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors	January 13, 2021	Active, not recruiting	1U54CA224079-01
clinical_trial	NCT02279433	A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	September 22, 2020	Completed	1U54CA224079-01
clinical_trial	NCT01804530	Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors	August 2, 2018	Terminated	1U54CA224079-01
clinical_trial	NCT02219711	Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer	January 30, 2020	Active, not recruiting	1U54CA224079-01
clinical_trial	NCT02184195	Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO)	June 18, 2021	Active, not recruiting	1U01CA224146-01
clinical_trial	NCT01482962	Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma	July 31, 2018	Completed	1U54CA224079-01
clinical_trial	NCT03066648	Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS	July 30, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT03381118	Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients	April 5, 2019	Terminated	1U54CA224019-01
clinical_trial	NCT01096602	Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission	August 3, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT01822509	Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant	June 24, 2021	Completed	1U54CA224019-01
clinical_trial	NCT01919619	Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies	August 13, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT01953692	A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)	August 4, 2021	Completed	1U54CA224019-01
clinical_trial	NCT02117219	Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome	May 10, 2019	Completed	1U54CA224019-01
clinical_trial	NCT02275533	Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy	September 2, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02397720	Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia	January 15, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT02464657	Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)	June 18, 2020	Completed	1U54CA224019-01
clinical_trial	NCT02530463	Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome	January 15, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT02532231	Nivolumab in AML in Remission at High Risk for Relapse	February 13, 2020	Recruiting	1U54CA224019-01
clinical_trial	NCT02599649	Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)	January 14, 2020	Terminated	1U54CA224019-01
clinical_trial	NCT02708641	A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients &#8805; 60 With AML	August 10, 2021	Completed	1U54CA224019-01
clinical_trial	NCT02768792	High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML	September 5, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02771197	Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant	September 5, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02775903	An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)	August 23, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02845297	Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (&#8805;65 Years) AML Patients	May 19, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02846376	Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002)	September 16, 2020	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02890329	Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	September 8, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT02935361	Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed	April 6, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02936752	Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents	July 2, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02953561	Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia	October 22, 2020	Terminated	1U54CA224019-01
clinical_trial	NCT02981914	Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation	June 30, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT02985554	Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies	June 25, 2020	Terminated	1U54CA224019-01
clinical_trial	NCT02996474	Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia	June 9, 2020	Completed	1U54CA224019-01
clinical_trial	NCT03059485	DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission	October 22, 2020	Recruiting	1U54CA224019-01
clinical_trial	NCT03092674	Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	September 8, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT03094637	Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome	May 17, 2019	Recruiting	1U54CA224019-01
clinical_trial	NCT03146468	Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation (NIVALLO)	September 28, 2020	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT03154827	A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study	May 18, 2020	Terminated	1U54CA224019-01
clinical_trial	NCT03259516	Nivolumab With Chemotherapy in Refractory MDS	April 5, 2019	Terminated	1U54CA224019-01
clinical_trial	NCT03286114	Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab	May 27, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT03291353	Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia	April 19, 2019	Withdrawn
                  
      <!--	1U54CA224019-01
clinical_trial	NCT03358719	DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia	June 2, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT03390296	OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	February 12, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT03395873	Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy	August 21, 2019	Terminated	1U54CA224019-01
clinical_trial	NCT02233595	Evaluation of Rectal Cancer Treatment Response Using PET/MRI (Rectal PET/MRI)	August 13, 2019	Terminated	1R33CA225310-01
clinical_trial	NCT02902757	FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma	February 4, 2021	Recruiting	1R33CA225310-01
clinical_trial	NCT02773238	FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging	July 9, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT02492867	A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer	February 10, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT00574353	Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients	April 8, 2020	Withdrawn	1R33CA225310-01
clinical_trial	NCT02016872	Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients	January 5, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT01212354	Impact of Selective Radiation Dose Escalation and Tumour Hypoxia Status on Locoregional Tumour Control After Radiochemotherapy of HNT (Escalox)	February 9, 2016	Recruiting	1R33CA225310-01
clinical_trial	NCT01507428	Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer	April 29, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT01542177	A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer	December 16, 2019	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT01549730	Cervix Hypoxia FAZA	April 13, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT02328300	FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions	November 14, 2018	Withdrawn
                  
      <!--	1R33CA225310-01
clinical_trial	NCT02456246	Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT (SBRT FLT-PET)	April 29, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT01666808	FACBC Outcomes for Post Prostatectomy	February 2, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT03115333	DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma	May 21, 2020	Recruiting	1R33CA225310-01
clinical_trial	NCT02031250	Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer	January 28, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT03151642	A PILOT STUDY OF DIFFUSION WEIGHTED MRI TO ASSESS ESOPHAGEAL TUMOR RESONSE TO NEOADJUVANT CHEMORADIATION	April 26, 2021	Completed	1R33CA225310-01
clinical_trial	NCT02497573				1R33CA225310-01
clinical_trial	NCT00581906	Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors	March 2, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT02319239	Prostate Cancer Stereotactic Radiotherapy (ESKO)	October 28, 2020	Completed	1R33CA225310-01
clinical_trial	NCT02233374	Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET (PRISM)	September 18, 2019	Completed	1R33CA225310-01
clinical_trial	NCT02415816	Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas	January 7, 2021	Recruiting	1R33CA225310-01
clinical_trial	NCT01992861	MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer	August 24, 2021	Recruiting	1R33CA225310-01
clinical_trial	NCT02137759	MRSI to Predict Response to RT/TMZ &#177; Belinostat in GBM	September 5, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT01507506	Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma (SPECTRO GLIO)	January 12, 2021	Terminated	1R33CA225310-01
clinical_trial	NCT03137888	Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma	March 1, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT01727076	Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer	September 15, 2017	Completed	2UM1CA154967-07
clinical_trial	NCT01781429	Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies	March 20, 2020	Completed	1U54CA224083-01
clinical_trial	NCT02608229	BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer	April 21, 2021	Terminated	1U54CA224083-01
clinical_trial	NCT01714739	A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors	December 14, 2020	Completed	1R33CA225291-01
clinical_trial	NCT01714739	A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors	December 14, 2020	Completed	1U54CA224070-01
clinical_trial	NCT02083484	Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)	January 26, 2018	No longer available	1R33CA225291-01
clinical_trial	NCT02083484	Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)	January 26, 2018	No longer available	1U54CA224070-01
clinical_trial	NCT01543698	A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors	May 10, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT01543698	A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors	May 10, 2021	Active, not recruiting	1U54CA224070-01
clinical_trial	NCT01072175	Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 &amp; GSK1120212	July 5, 2019	Completed	1R33CA225291-01
clinical_trial	NCT01072175	Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 &amp; GSK1120212	July 5, 2019	Completed	1U54CA224070-01
clinical_trial	NCT00949702	A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma	July 25, 2017	Completed	1R33CA225291-01
clinical_trial	NCT00949702	A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma	July 25, 2017	Completed	1U54CA224070-01
clinical_trial	NCT01783938	Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)	August 13, 2021	Completed	1R33CA225291-01
clinical_trial	NCT01783938	Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)	August 13, 2021	Completed	1U54CA224070-01
clinical_trial	NCT01006980	A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)	September 28, 2016	Completed	1R33CA225291-01
clinical_trial	NCT01006980	A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)	September 28, 2016	Completed	1U54CA224070-01
clinical_trial	NCT01231906	Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma	May 6, 2021	Active, not recruiting	3R01CA204915-02S1
clinical_trial	NCT02259621	Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC (NA_00092076)	July 27, 2021	Recruiting	1U01CA224348-01
clinical_trial	NCT00106015	Diamond Blackfan Anemia Registry (DBAR) (DBAR)	March 4, 2021	Recruiting	1R01CA211723-01A1
clinical_trial	NCT02996500	Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate	February 27, 2020	Completed	1U54CA224019-01
clinical_trial	NCT03328078	A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies	May 5, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT03328078	A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies	May 5, 2021	Recruiting	1U54CA224083-01
clinical_trial	NCT02891603	A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression	August 18, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT01235871	A Single and Multiple-Dose Study of SB1578	April 20, 2012	Completed	1U54CA224019-01
clinical_trial	NCT01728402	Pathogenesis of Hematologic Malignancies	August 30, 2021	Enrolling by invitation	1U54CA224019-01
clinical_trial	NCT03456700	Auranofin and Sirolimus in Treating Participants With Ovarian Cancer	March 16, 2021	Active, not recruiting	3U54CA224065-01S1
clinical_trial	NCT01195922	Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma	December 6, 2017	Completed	1R33CA225291-01
clinical_trial	NCT01657682	A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations	July 20, 2020	Completed	3R01CA182543-05S2
clinical_trial	NCT01657682	A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations	July 20, 2020	Completed	1U54CA224019-01
clinical_trial	NCT03123783	CD40 Agonistic Antibody APX005M in Combination With Nivolumab	May 4, 2021	Completed	1U01CA224348-01
clinical_trial	NCT02376699	Safety Study of SEA-CD40 in Cancer Patients	March 16, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT03270176				1U01CA224348-01
clinical_trial	NCT01502293	Trial of pIL-12 Electroporation Malignant Melanoma (IL-12MEL)	October 9, 2019	Completed	1U01CA224348-01
clinical_trial	NCT02698189	A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)	July 13, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02698189	A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)	July 13, 2021	Active, not recruiting	5R01CA176745-09
clinical_trial	NCT02308761	A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome	December 11, 2017	Completed	1U54CA224019-01
clinical_trial	NCT02308761	A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome	December 11, 2017	Completed	5R01CA176745-09
clinical_trial	NCT02391480	A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer	November 29, 2019	Completed	1U54CA224019-01
clinical_trial	NCT02683395	A Study of PLX51107 in Advanced Malignancies	December 24, 2018	Terminated	1U54CA224019-01
clinical_trial	NCT02606123	Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer	March 1, 2018	Terminated	1U54CA224079-01
clinical_trial	NCT02339558	Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer	September 13, 2019	Completed	2UM1CA154967-07
clinical_trial	NCT01522469	Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations	June 28, 2018	Completed	1U54CA224019-01
clinical_trial	NCT02639026	Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers	March 9, 2021	Active, not recruiting	1U01CA224146-01
clinical_trial	NCT02639026	Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers	March 9, 2021	Active, not recruiting	1U01CA224175-01
clinical_trial	NCT02639026	Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers	March 9, 2021	Active, not recruiting	1U01CA224193-01
clinical_trial	NCT02648282	Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer	August 9, 2021	Active, not recruiting	1U01CA224146-01
clinical_trial	NCT02648282	Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer	August 9, 2021	Active, not recruiting	1U01CA224175-01
clinical_trial	NCT02648282	Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer	August 9, 2021	Active, not recruiting	1U01CA224193-01
clinical_trial	NCT03245541	Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer	August 9, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT03245541	Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer	August 9, 2021	Recruiting	1U01CA224175-01
clinical_trial	NCT03245541	Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer	August 9, 2021	Recruiting	1U01CA224193-01
clinical_trial	NCT03190265	Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer	August 20, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT03190265	Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer	August 20, 2021	Recruiting	1U01CA224175-01
clinical_trial	NCT03190265	Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer	August 20, 2021	Recruiting	1U01CA224193-01
clinical_trial	NCT02451982	Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer	March 22, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT02451982	Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer	March 22, 2021	Recruiting	1U01CA224175-01
clinical_trial	NCT02451982	Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer	March 22, 2021	Recruiting	1U01CA224193-01
clinical_trial	NCT03153410	Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas	August 19, 2021	Active, not recruiting	1U01CA224146-01
clinical_trial	NCT03153410	Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas	August 19, 2021	Active, not recruiting	1U01CA224175-01
clinical_trial	NCT03153410	Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas	August 19, 2021	Active, not recruiting	1U01CA224193-01
clinical_trial	NCT03006302	Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer	August 20, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT03006302	Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer	August 20, 2021	Recruiting	1U01CA224175-01
clinical_trial	NCT03006302	Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer	August 20, 2021	Recruiting	1U01CA224193-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	July 30, 2021	Active, not recruiting	1U01CA224146-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	July 30, 2021	Active, not recruiting	1U01CA224175-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	July 30, 2021	Active, not recruiting	1U01CA224193-01
clinical_trial	NCT02758587	Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)	March 19, 2018	Recruiting	1U01CA224146-01
clinical_trial	NCT02758587	Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)	March 19, 2018	Recruiting	1U01CA224175-01
clinical_trial	NCT02758587	Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)	March 19, 2018	Recruiting	1U01CA224193-01
clinical_trial	NCT02546531	Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer	July 20, 2021	Completed	1U01CA224146-01
clinical_trial	NCT02546531	Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer	July 20, 2021	Completed	1U01CA224175-01
clinical_trial	NCT02546531	Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer	July 20, 2021	Completed	1U01CA224193-01
clinical_trial	NCT02546531	Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer	July 20, 2021	Completed	1U54CA224083-01
clinical_trial	NCT03481920	A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer	August 22, 2019	Terminated	1U01CA224146-01
clinical_trial	NCT03481920	A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer	August 22, 2019	Terminated	1U01CA224175-01
clinical_trial	NCT03481920	A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer	August 22, 2019	Terminated	1U01CA224193-01
clinical_trial	NCT03193190	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)	August 5, 2021	Active, not recruiting	1U01CA224146-01
clinical_trial	NCT03193190	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)	August 5, 2021	Active, not recruiting	1U01CA224175-01
clinical_trial	NCT03193190	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)	August 5, 2021	Active, not recruiting	1U01CA224193-01
clinical_trial	NCT03634332	Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC	May 7, 2019	Unknown	1U01CA224146-01
clinical_trial	NCT03634332	Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC	May 7, 2019	Unknown	1U01CA224175-01
clinical_trial	NCT03634332	Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC	May 7, 2019	Unknown	1U01CA224193-01
clinical_trial	NCT02436668	Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)	December 30, 2020	Completed	1U01CA224146-01
clinical_trial	NCT02436668	Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)	December 30, 2020	Completed	1U01CA224175-01
clinical_trial	NCT02436668	Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)	December 30, 2020	Completed	1U01CA224193-01
clinical_trial	NCT03496662	BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)	July 23, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT03496662	BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)	July 23, 2021	Recruiting	1U01CA224175-01
clinical_trial	NCT03496662	BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)	July 23, 2021	Recruiting	1U01CA224193-01
clinical_trial	NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)	June 10, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)	June 10, 2021	Recruiting	1U01CA224175-01
clinical_trial	NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)	June 10, 2021	Recruiting	1U01CA224193-01
clinical_trial	NCT00798213	SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)	February 4, 2015	Terminated	1U24CA224067-01
clinical_trial	NCT00937937	Dinaciclib in Treating Patients With Stage IV Melanoma	August 5, 2021	Active, not recruiting	1U24CA224067-01
clinical_trial	NCT03253679	AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification	August 16, 2021	Suspended
                  
      <!--	1U24CA224067-01
clinical_trial	NCT03271372	Adjuvant Avelumab in Merkel Cell Cancer (ADAM)	May 27, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT02488759	An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (CheckMate358)	September 10, 2020	Active, not recruiting	2UM1CA154967-07
clinical_trial	NCT01659151	Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer &amp; High Dose IL-2 Metastatic Melanoma	June 15, 2021	Active, not recruiting	1U54CA224070-01
clinical_trial	NCT02974725	A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma	September 8, 2021	Recruiting	1U54CA224068-01
clinical_trial	NCT03478397	Evaluation of a mHealth Intervention to Increase Adherence to Triage of Self-collected HPV+ Women (ATICA Project) (ATICA)	April 6, 2021	Completed	1R01CA218306-01
clinical_trial	NCT02358031	A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)	October 23, 2020	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT02358031	A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)	October 23, 2020	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02358031	A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)	October 23, 2020	Active, not recruiting	1U01DE029255-01
clinical_trial	NCT02741570	Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651)	April 19, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT02741570	Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651)	April 19, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT00771641	Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck	January 24, 2014	Completed	1R33CA225291-01
clinical_trial	NCT00771641	Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck	January 24, 2014	Completed	1U01DE028227-01
clinical_trial	NCT03383094	Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer	February 8, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT03383094	Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer	February 8, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT03317327	REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors (REPORT)	September 30, 2019	Recruiting	1R33CA225291-01
clinical_trial	NCT03317327	REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors (REPORT)	September 30, 2019	Recruiting	1U01DE028227-01
clinical_trial	NCT03546582	SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE)	August 3, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT03546582	SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE)	August 3, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT02296684	Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma	August 30, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT02296684	Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma	August 30, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03051906	Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer (DUCRO-HN)	November 22, 2017	Not yet recruiting	1R33CA225291-01
clinical_trial	NCT03051906	Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer (DUCRO-HN)	November 22, 2017	Not yet recruiting	1U01DE028227-01
clinical_trial	NCT02999087	Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (REACH)	November 4, 2020	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT02999087	Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (REACH)	November 4, 2020	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02764593	Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer	August 3, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT02764593	Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer	August 3, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03247712	Neoadjuvant Immunoradiotherapy in Head &amp; Neck Cancer	May 20, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT03247712	Neoadjuvant Immunoradiotherapy in Head &amp; Neck Cancer	May 20, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03673735	Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC (ADHERE)	May 10, 2021	Withdrawn
                  
      <!--	1R33CA225291-01
clinical_trial	NCT03673735	Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC (ADHERE)	May 10, 2021	Withdrawn
                  
      <!--	1U01DE028227-01
clinical_trial	NCT03529422	Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN	May 11, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT03529422	Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN	May 11, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT03426657	Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC	June 11, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT03426657	Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC	June 11, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT03509012	Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)	July 21, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT03509012	Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)	July 21, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03539198	Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer	April 5, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT03539198	Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer	April 5, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03085719	Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN	November 13, 2020	Recruiting	1R33CA225291-01
clinical_trial	NCT03085719	Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN	November 13, 2020	Recruiting	1U01DE028227-01
clinical_trial	NCT03283605	Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas	May 27, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT03283605	Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas	May 27, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT03313804	Priming Immunotherapy in Advanced Disease With Radiation	June 14, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT03313804	Priming Immunotherapy in Advanced Disease With Radiation	June 14, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT02777385	Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer	April 6, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT02777385	Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer	April 6, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT03349710	Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer	August 9, 2021	Completed	1R33CA225291-01
clinical_trial	NCT03349710	Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer	August 9, 2021	Completed	1U01DE028227-01
clinical_trial	NCT02892201	Pembrolizumab in HNSCC With Residual Disease After Radiation	July 15, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT02892201	Pembrolizumab in HNSCC With Residual Disease After Radiation	July 15, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02841748	A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study	January 7, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT02841748	A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study	January 7, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT03040999	Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)	April 19, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT03040999	Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)	April 19, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02952586	Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)	June 22, 2021	Terminated	1R33CA225291-01
clinical_trial	NCT02952586	Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)	June 22, 2021	Terminated	1U01DE028227-01
clinical_trial	NCT02952586	Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)	June 22, 2021	Terminated	1U01DE029188-01
clinical_trial	NCT03452137	A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck	August 5, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT03452137	A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck	August 5, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT01302834	Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer	February 23, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT01302834	Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer	February 23, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT01040832	EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Na&#239;ve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	January 30, 2017	Completed	1R33CA225291-01
clinical_trial	NCT01040832	EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Na&#239;ve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	January 30, 2017	Completed	1U01DE028227-01
clinical_trial	NCT01334177	TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck	March 5, 2015	Completed	1R33CA225291-01
clinical_trial	NCT01334177	TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck	March 5, 2015	Completed	1U01DE028227-01
clinical_trial	NCT01360827	EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck	June 17, 2014	Terminated	1R33CA225291-01
clinical_trial	NCT01360827	EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck	June 17, 2014	Terminated	1U01DE028227-01
clinical_trial	NCT01468896	Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery	March 22, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT01468896	Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery	March 22, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT01836029	Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	October 29, 2019	Completed	1R33CA225291-01
clinical_trial	NCT01836029	Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	October 29, 2019	Completed	1U01DE028227-01
clinical_trial	NCT01935921	Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer	June 15, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT01935921	Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer	June 15, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02110082	Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer	April 19, 2017	Completed	1R33CA225291-01
clinical_trial	NCT02110082	Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer	April 19, 2017	Completed	1U01DE028227-01
clinical_trial	NCT02124850	A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab	October 25, 2019	Terminated	1R33CA225291-01
clinical_trial	NCT02124850	A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab	October 25, 2019	Terminated	1U01DE028227-01
clinical_trial	NCT02633800	Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )	January 7, 2019	Terminated	1R33CA225291-01
clinical_trial	NCT02633800	Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )	January 7, 2019	Terminated	1U01DE028227-01
clinical_trial	NCT02643550	Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	February 9, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT02643550	Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	February 9, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02938273	Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)	December 11, 2019	Completed	1R33CA225291-01
clinical_trial	NCT02938273	Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)	December 11, 2019	Completed	1U01DE028227-01
clinical_trial	NCT03082534	Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma	March 11, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT03082534	Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma	March 11, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT03370276	Cetuximab &amp; Nivolumab in Patients With Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma	September 16, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT03370276	Cetuximab &amp; Nivolumab in Patients With Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma	September 16, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03494322	EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer (EACH)	November 5, 2020	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT03494322	EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer (EACH)	November 5, 2020	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03498378	Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	October 19, 2020	Recruiting	1R33CA225291-01
clinical_trial	NCT03498378	Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	October 19, 2020	Recruiting	1U01DE028227-01
clinical_trial	NCT03498378	Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	October 19, 2020	Recruiting	1U01CA233100-01
clinical_trial	NCT01860430	Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer	June 15, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT01860430	Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer	June 15, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02581137	Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion	September 16, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT02581137	Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion	September 16, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03074513	Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors	February 24, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT03074513	Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors	February 24, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02950766	NeoVax Plus Ipilimumab in Renal Cell Carcinoma	March 3, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03422094	Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma	April 23, 2021	Terminated	1U01CA233100-01
clinical_trial	NCT03361852	Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma	August 25, 2021	Not yet recruiting	1U01CA233100-01
clinical_trial	NCT03219450	A Personalized Neoantigen Cancer Vaccine in Treatment Na&#239;ve, Asymptomatic Patients With IGHV Unmutated CLL.	August 26, 2021	Not yet recruiting	1U01CA233100-01
clinical_trial	NCT03063632	Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and S&#233;zary Syndrome and Advanced Synovial Sarcoma	May 14, 2021	Active, not recruiting	2UM1CA154967-07
clinical_trial	NCT03063632	Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and S&#233;zary Syndrome and Advanced Synovial Sarcoma	May 14, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02614456	Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors	November 29, 2019	Completed	1U01CA233100-01
clinical_trial	NCT02646748	Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors	December 4, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03012230	Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer	May 25, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03425006	Pembrolizumab and Itacitinib (INCB039110) for NSCLC	September 16, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03172936	Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	February 24, 2021	Completed	1U01CA233100-01
clinical_trial	NCT03172936	Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	February 24, 2021	Completed	1U54CA244719-01
clinical_trial	NCT03147287	Palbociclib After CDK and Endocrine Therapy (PACE)	August 23, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03573648	Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (ImmunoADAPT)	June 2, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03294694	Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer	December 29, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02779751	A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer	March 4, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02947165	Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.	July 8, 2021	Completed	1U01CA233100-01
clinical_trial	NCT02734160	A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer	August 5, 2019	Completed	1U01CA233100-01
clinical_trial	NCT02734160	A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer	August 5, 2019	Completed	1U54CA224083-01
clinical_trial	NCT02423343	A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma	September 9, 2021	Completed	1U01CA233100-01
clinical_trial	NCT02517398	MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors	March 22, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03620201	M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer	June 4, 2020	Recruiting	1U01CA233100-01
clinical_trial	NCT03631706	M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)	October 20, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02675439	Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	July 9, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03010176	Study of MK-1454 Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)	April 21, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03010176	Study of MK-1454 Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)	April 21, 2021	Active, not recruiting	1U54CA244719-01
clinical_trial	NCT02457910	Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer	February 23, 2021	Active, not recruiting	1U2CCA233280-01
clinical_trial	NCT02456857	Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative	April 13, 2021	Active, not recruiting	1U2CCA233280-01
clinical_trial	NCT03805399	FUSCC Refractory TNBC Umbrella (FUTURE) (FUTURE)	February 5, 2020	Recruiting	1U2CCA233280-01
clinical_trial	NCT03487666	OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease	September 16, 2021	Active, not recruiting	1U2CCA233280-01
clinical_trial	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)	August 27, 2021	Recruiting	1U2CCA233280-01
clinical_trial	NCT03801369	Olaparib and Durvalumab in Treating Patients With Metastatic Triple Negative Breast Cancer	June 11, 2021	Recruiting	1U2CCA233280-01
clinical_trial	NCT01023386	A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer	April 13, 2010	Completed	1U54CA231652-01
clinical_trial	NCT00818480	An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155	September 4, 2015	Completed	1U54CA231652-01
clinical_trial	NCT01007292	A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment	October 19, 2015	Completed	1U54CA231652-01
clinical_trial	NCT01009775	A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma	September 4, 2015	Completed	1U54CA231652-01
clinical_trial	NCT01038804	A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer	September 18, 2013	Completed	1U54CA231652-01
clinical_trial	NCT00498914	Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects	September 4, 2015	Terminated	1U54CA231652-01
clinical_trial	NCT01100931	A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)	October 19, 2015	Completed	1U54CA231652-01
clinical_trial	NCT00514267	An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors	August 13, 2015	Completed	1U54CA231652-01
clinical_trial	NCT00281541	A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma	June 7, 2012	Completed	1U54CA231652-01
clinical_trial	NCT00328588	LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy	January 2, 2008	Completed	1U54CA231652-01
clinical_trial	NCT00257478	A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy	June 7, 2012	Completed	1U54CA231652-01
clinical_trial	NCT01747551	FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer	February 10, 2020	Completed	1U01CA224348-01
clinical_trial	NCT00756106	MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma	May 13, 2020	Terminated	1U01CA224348-01
clinical_trial	NCT01004172	Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases	December 14, 2018	Completed	1U01CA224348-01
clinical_trial	NCT01032122	Rituximab in Metastatic Melanoma	April 25, 2013	Terminated	1U54CA224068-01
clinical_trial	NCT01376713	Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma	October 6, 2015	Completed	1U54CA224068-01
clinical_trial	NCT01376713	Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma	October 6, 2015	Completed	1U54CA224070-01
clinical_trial	NCT01307267	A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab	March 17, 2020	Completed	1U54CA224068-01
clinical_trial	NCT02579226	A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.	May 1, 2020	Completed	3R01CA204915-02S1
clinical_trial	NCT03630120	Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer	July 14, 2021	Terminated	1U54CA224081-01
clinical_trial	NCT03543969	Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma	September 14, 2021	Recruiting	1U54CA224081-01
clinical_trial	NCT03511196	Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer	July 19, 2021	Active, not recruiting	1U54CA224081-01
clinical_trial	NCT02415621	Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer	May 24, 2021	Active, not recruiting	1U54CA224081-01
clinical_trial	NCT03227926	Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance (CHRONOS)	August 31, 2021	Active, not recruiting	1U54CA224081-01
clinical_trial	NCT03259009	RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO) (RASINTRO)	September 11, 2017	Unknown	1U54CA224081-01
clinical_trial	NCT02296203	Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). (CRICKET)	February 15, 2018	Unknown	1U54CA224081-01
clinical_trial	NCT01158521	Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer	September 12, 2018	Completed	1U54CA224081-01
clinical_trial	NCT03088930	Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer	April 23, 2021	Completed	1U54CA224081-01
clinical_trial	NCT03433469	Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery	June 3, 2021	Recruiting	1U54CA224081-01
clinical_trial	NCT02443948	Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST)	February 14, 2017	Unknown	1U54CA224081-01
clinical_trial	NCT03691012	Circulating Tumour DNA as a Marker of Residual Disease &amp; Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer	November 3, 2020	Recruiting	1U54CA224081-01
clinical_trial	NCT02245100	Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer	September 1, 2021	Active, not recruiting	1U54CA224081-01
clinical_trial	NCT03637686	Circulating Tumor DNA Analysis to Optimize Treatment for Patients With Colorectal Cancer (IMPROVE)	January 14, 2021	Recruiting	1U54CA224081-01
clinical_trial	NCT02883517	Cell-free Circulating DNA in Primary Cutaneous Lymphomas (MATULILA)	February 23, 2017	Unknown	1U54CA224081-01
clinical_trial	NCT03414034	Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer	March 23, 2021	Recruiting	3U54CA224065-01S1
clinical_trial	NCT03303339	Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)	May 27, 2021	Active, not recruiting	3U54CA224065-01S1
clinical_trial	NCT02864992	Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)	June 11, 2021	Active, not recruiting	3U54CA224065-01S1
clinical_trial	NCT02952534	A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)	August 30, 2021	Completed	1U54CA224079-01
clinical_trial	NCT02987543	Study of Olaparib (Lynparza&#8482;) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)	August 4, 2021	Active, not recruiting	1U54CA224079-01
clinical_trial	NCT02854436	An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies (Galahad)	September 10, 2021	Active, not recruiting	1U54CA224079-01
clinical_trial	NCT02525068	A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC (RE-AKT)	August 8, 2018	Unknown	1U54CA224079-01
clinical_trial	NCT03310541	AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations	July 6, 2021	Active, not recruiting	1U54CA224079-01
clinical_trial	NCT01747486	Dose Optimization Trial of CD19 Redirected Autologous T Cells	August 30, 2019	Completed	1R01CA226983-01
clinical_trial	NCT01029366	CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy	June 26, 2019	Completed	1R01CA226983-01
clinical_trial	NCT01821729	Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer	September 25, 2020	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT01821729	Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer	September 25, 2020	Active, not recruiting	1U54CA224083-01
clinical_trial	NCT03563248	Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer	January 20, 2021	Recruiting	1U01CA224348-01
clinical_trial	NCT03563248	Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer	January 20, 2021	Recruiting	1U54CA224083-01
clinical_trial	NCT02595866	Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms	August 5, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT02639546	Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi)	July 2, 2021	Active, not recruiting	1U2CCA233262-01
clinical_trial	NCT03095248	Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601)	July 23, 2021	Recruiting	1U2CCA233262-01
clinical_trial	NCT02523014	Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas	August 17, 2021	Suspended
                  
      <!--	1U2CCA233262-01
clinical_trial	NCT02831257	AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas	December 22, 2020	Completed	1U2CCA233262-01
clinical_trial	NCT03071874	Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas	January 20, 2021	Active, not recruiting	1U2CCA233262-01
clinical_trial	NCT03744247	Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC	May 2, 2019	Withdrawn
                  
      <!--	1U01CA224348-01
clinical_trial	NCT03434379	A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150] (IMbrave150)	July 22, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT01140347	A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)	December 28, 2015	Completed	1U01CA224348-01
clinical_trial	NCT02435433	A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2)	July 30, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT02060188	An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread (CheckMate142)	November 6, 2019	Active, not recruiting	1U01CA233056-01
clinical_trial	NCT02460198	Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)	March 22, 2021	Completed	1U01CA233056-01
clinical_trial	NCT03631641	Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy	May 15, 2020	Active, not recruiting	1U01CA233056-01
clinical_trial	NCT01461148	Vaccination Against MSI Colorectal Cancer	June 23, 2015	Completed	1U01CA233056-01
clinical_trial	NCT01461148	Vaccination Against MSI Colorectal Cancer	June 23, 2015	Completed	1U01CA233097-01
clinical_trial	NCT01885702	Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI	December 9, 2020	Active, not recruiting	1U01CA233056-01
clinical_trial	NCT02657005	TK216 in Patients With Relapsed or Refractory Ewing Sarcoma	August 23, 2021	Recruiting	3R01CA204915-02S1
clinical_trial	NCT00070109	Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors	September 14, 2018	Completed	3R01CA204915-02S1
clinical_trial	NCT03600649	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas	August 11, 2021	Recruiting	3R01CA204915-02S1
clinical_trial	NCT03600649	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas	August 11, 2021	Recruiting	1U54CA231641-01
clinical_trial	NCT03637491	A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors	July 23, 2021	Terminated	1U01DE028233-01
clinical_trial	NCT03598270	Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA)	August 13, 2021	Recruiting	1U01DE028233-01
clinical_trial	NCT01240538	Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors	May 13, 2014	Completed	1U01CA232488-01
clinical_trial	NCT01240538	Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors	May 13, 2014	Completed	1U54CA232561-01A1
clinical_trial	NCT01048892	Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features	January 30, 2014	Completed	1U01CA232488-01
clinical_trial	NCT01048892	Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features	January 30, 2014	Completed	1U54CA232561-01A1
clinical_trial	NCT02457845	HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors	July 8, 2021	Active, not recruiting	1U01CA232488-01
clinical_trial	NCT02457845	HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors	July 8, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT03043391	Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children	July 13, 2021	Active, not recruiting	1U01CA232488-01
clinical_trial	NCT03043391	Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children	July 13, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02756845	Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors	August 19, 2021	Recruiting	1U01CA232488-01
clinical_trial	NCT02756845	Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors	August 19, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT00931931	HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors	March 21, 2018	Completed	1U01CA232488-01
clinical_trial	NCT00931931	HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors	March 21, 2018	Completed	1U54CA232561-01A1
clinical_trial	NCT01326104	Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor (Re-MATCH)	August 11, 2021	Active, not recruiting	1U01CA232488-01
clinical_trial	NCT01326104	Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor (Re-MATCH)	August 11, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02932956	Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP)	January 8, 2021	Recruiting	1U01CA232488-01
clinical_trial	NCT02932956	Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP)	January 8, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03500991	HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors	March 15, 2021	Recruiting	1U01CA232488-01
clinical_trial	NCT03500991	HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors	March 15, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03638167	EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors	March 15, 2021	Recruiting	1U01CA232488-01
clinical_trial	NCT03638167	EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors	March 15, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02315612	Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies	September 5, 2021	Recruiting	1U01CA232488-01
clinical_trial	NCT02315612	Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies	September 5, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02772198	T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies	November 3, 2020	Recruiting	1U01CA232488-01
clinical_trial	NCT02772198	T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies	November 3, 2020	Recruiting	1U54CA232561-01A1
clinical_trial	NCT01555892	Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE (GRALE)	December 23, 2020	Recruiting	1U01CA232488-01
clinical_trial	NCT01555892	Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE (GRALE)	December 23, 2020	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02892695	PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma	December 6, 2016	Unknown	1U01CA232488-01
clinical_trial	NCT02892695	PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma	December 6, 2016	Unknown	1U54CA232561-01A1
clinical_trial	NCT02573896	Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells	January 20, 2021	Recruiting	1U01CA232488-01
clinical_trial	NCT02573896	Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells	January 20, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02650648	Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma	October 5, 2020	Active, not recruiting	1U01CA232488-01
clinical_trial	NCT02650648	Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma	October 5, 2020	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT03209869	Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2	August 5, 2021	Suspended
                  
      <!--	1U01CA232488-01
clinical_trial	NCT03209869	Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2	August 5, 2021	Suspended
                  
      <!--	1U54CA232561-01A1
clinical_trial	NCT03420963	Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors	April 29, 2021	Recruiting	1U01CA232488-01
clinical_trial	NCT03420963	Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors	April 29, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02100891	Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR)	March 24, 2021	Active, not recruiting	1U01CA232488-01
clinical_trial	NCT02100891	Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR)	March 24, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT01823198	Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	December 4, 2020	Active, not recruiting	1U01CA232488-01
clinical_trial	NCT01823198	Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	December 4, 2020	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT01904136	Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia	February 10, 2021	Active, not recruiting	1U01CA232488-01
clinical_trial	NCT01904136	Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia	February 10, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02809092	Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia	October 15, 2019	Unknown	1U01CA232488-01
clinical_trial	NCT02809092	Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia	October 15, 2019	Unknown	1U54CA232561-01A1
clinical_trial	NCT01898793	Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	May 21, 2021	Recruiting	1U01CA232488-01
clinical_trial	NCT01898793	Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	May 21, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT01619761	NK Cells in Cord Blood Transplantation	February 11, 2020	Active, not recruiting	1U01CA232488-01
clinical_trial	NCT01619761	NK Cells in Cord Blood Transplantation	February 11, 2020	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT01084252	Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies	April 20, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03733717	Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma	August 2, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02812706	Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients (Islands)	September 29, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02514668	A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma	March 26, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02960555	Isatuximab in Treating Patients With High Risk Smoldering Plasma Cell Myeloma	May 13, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT01749969	SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients	March 26, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02283775	SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients (PomdeSAR)	July 9, 2021	Completed	2P01CA155258-06
clinical_trial	NCT02990338	Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients (ICARIA-MM)	February 24, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02332850	Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma	July 21, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03275285	Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA)	June 9, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03319667	Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ)	July 12, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03617731	Trial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)	October 8, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03104842	Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone	February 3, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03194867	Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients	March 26, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT04083898	Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma	April 5, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT02513186	Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation	June 4, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT04045795	Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)	June 3, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT02413489	An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma	June 26, 2018	Terminated	2P01CA155258-06
clinical_trial	NCT02927925	A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type	January 14, 2021	Completed	2P01CA155258-06
clinical_trial	NCT02999633	Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia (ISLAY)	January 18, 2020	Terminated	2P01CA155258-06
clinical_trial	NCT03860844	Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS)	June 8, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03499808	S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis	June 10, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03769181	A Study of Isatuximab-based Therapy in Participants With Lymphoma	July 27, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03367819	Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies	April 21, 2021	Completed	2P01CA155258-06
clinical_trial	NCT03637764	Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies	November 25, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03555149	A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)	August 18, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03869190	Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)	September 14, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03201965	A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis	August 23, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT04131309	A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis	February 5, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03473730	Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer	May 13, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT04088903	Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation	October 28, 2020	Withdrawn
                  
      <!--	2P01CA155258-06
clinical_trial	NCT03277105	A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma	July 23, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01421186	A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma	September 16, 2020	Completed	2P01CA155258-06
clinical_trial	NCT02219256	A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants	May 3, 2017	Completed	2P01CA155258-06
clinical_trial	NCT03439280	A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)	March 19, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03984097	A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)	August 5, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02076009	A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma	August 9, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02136134	Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma	August 24, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02252172	Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma	August 20, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02195479	A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma	July 23, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02541383	A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma (Cassiopeia)	December 7, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02393859	Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)	December 8, 2020	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02435849	Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse. Determine Feasibility and Safety of CTL019 Therapy in Pediatric Patients With High Risk B-cell ALL That Relapsed &lt; 6 Months Post All-HSCT. (ELIANA)	June 30, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02559778	Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN)	August 23, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03837899	Durvalumab and Tremelimumab for Pediatric Malignancies	September 5, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT04044378	Famitinib Plus Camrelizumab &amp; Famitinib Alone &amp; Famitinib Plus Ifosfamide in Advanced Osteosarcoma	May 19, 2020	Withdrawn
                  
      <!--	1U54CA232561-01A1
clinical_trial	NCT02311621	Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01	April 27, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02311621	Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01	April 27, 2021	Recruiting	1U54CA232568-01
clinical_trial	NCT03130959	An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908)	April 1, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT03618381	EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults	April 19, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03618381	EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults	April 19, 2021	Recruiting	1UG3CA244687-01
clinical_trial	NCT03334305	Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas (ACTION)	August 12, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03448393	CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies	September 5, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03448393	CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies	September 5, 2021	Recruiting	1U54CA232568-01
clinical_trial	NCT01192555	Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma (ATOMIC)	March 10, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02502708	Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors	June 4, 2020	Completed	1U54CA232561-01A1
clinical_trial	NCT02502708	Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors	June 4, 2020	Completed	1U01CA224151-01
clinical_trial	NCT03703050	Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)	July 7, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03907488	Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma	September 16, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02789228	Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST)	February 25, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03396575	Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (BRAVO)	July 13, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03911388				1U54CA232561-01A1
clinical_trial	NCT03178032	Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas	July 16, 2020	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02962167	Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT	June 30, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02444546	Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors	August 18, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT03495921	Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma (VITA)	August 18, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT00790413	Haploidentical Stem Cell Transplantation in Neuroblastoma	February 21, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02793466	Durvalumab in Pediatric and Adolescent Patients	January 30, 2019	Unknown	1U54CA232561-01A1
clinical_trial	NCT01860937	T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia	July 6, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT03006848	A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma	September 16, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT00634231	A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors	January 27, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02511132	A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma	February 4, 2021	Completed	1U54CA232561-01A1
clinical_trial	NCT03299309	PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma (PRiME)	May 25, 2021	Suspended
                  
      <!--	1U54CA232561-01A1
clinical_trial	NCT02028455	A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia	January 29, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02028455	A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia	January 29, 2021	Active, not recruiting	1U01CA247548-01
clinical_trial	NCT03643276	Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017	July 7, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03244306	A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (PLAT-04)	January 19, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT03244306	A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (PLAT-04)	January 19, 2021	Active, not recruiting	1U01CA247548-01
clinical_trial	NCT03186118	Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia	March 25, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03605589	Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma	April 1, 2021	Withdrawn
                  
      <!--	1U54CA232561-01A1
clinical_trial	NCT03330691	A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia	May 24, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03330691	A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia	May 24, 2021	Recruiting	1U01CA247548-01
clinical_trial	NCT03330691	A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia	May 24, 2021	Recruiting	1U54CA232568-01
clinical_trial	NCT00902044	Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma	August 24, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT00902044	Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma	August 24, 2021	Active, not recruiting	1U54CA232568-01
clinical_trial	NCT03769467	Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)	February 3, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02960230	H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas	August 25, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT01700946	Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma	August 24, 2021	Completed	1U54CA232561-01A1
clinical_trial	NCT01169584	Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients	January 21, 2016	Completed	1U54CA232561-01A1
clinical_trial	NCT03359018	Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (APFAO)	May 19, 2020	Completed	1U54CA232561-01A1
clinical_trial	NCT02403778	Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma	September 23, 2020	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT01130142	A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer	March 6, 2017	Completed	1U01CA224193-01
clinical_trial	NCT01130142	A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer	March 6, 2017	Completed	1U01CA224348-01
clinical_trial	NCT01130142	A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer	March 6, 2017	Completed	1U54CA224083-01
clinical_trial	NCT01850628	NSABP Biospecimen Discovery Project	September 10, 2020	Active, not recruiting	1U54CA233223-01
clinical_trial	NCT02424617	A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer	July 6, 2017	Unknown	1U54CA224081-01
clinical_trial	NCT01091831	Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects	November 6, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02406144	Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma	November 30, 2017	Completed	2P01CA155258-06
clinical_trial	NCT02253316	Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma	October 1, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02389517	Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant	January 7, 2021	Suspended
                  
      <!--	2P01CA155258-06
clinical_trial	NCT02659293	Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma	June 30, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02203643	Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. (FORTE)	April 29, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03896737	Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara	August 19, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03901963	A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA)	September 17, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT02874742	Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma	July 12, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02495922	A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG-HD6)	September 10, 2021	Completed	2P01CA155258-06
clinical_trial	NCT01850524	IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma	February 1, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03729804	Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) ((COBRA))	June 8, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03742297				2P01CA155258-06
clinical_trial	NCT03710603	Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma (Perseus)	August 26, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03710603	Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma (Perseus)	August 26, 2021	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT03652064	A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy	September 17, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01335399	Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)	October 26, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01668719	S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma	April 6, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02312258	A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)	November 10, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03748953	Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)	September 17, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03720041	Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma (FiTNEss)	June 15, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03733691	Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients	October 27, 2020	Recruiting	2P01CA155258-06
clinical_trial	NCT02891811	Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy	May 19, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT00058474	Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer	March 23, 2016	Unknown	1U01CA232859-01
clinical_trial	NCT03184571	Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC	May 29, 2020	Recruiting	1U24CA224316-01
clinical_trial	NCT02936609	Assessing Community Cancer Care After Insurance ExpanSionS (ACCESS)	August 30, 2021	Completed	1P50CA244289-01
clinical_trial	NCT03545763	Evaluating Control of Hypertension - Effect of Social Determinants (ECHOES)	March 23, 2021	Active, not recruiting	1P50CA244289-01
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	August 16, 2018	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	August 16, 2018	Active, not recruiting	1U2CCA233303-01
clinical_trial	NCT03433183	SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors	September 18, 2020	Recruiting	1UG3CA244687-01
clinical_trial	NCT02008877	SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)	May 15, 2019	Completed	1UG3CA244687-01
clinical_trial	NCT02584647	PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors (PLX3397)	August 31, 2021	Recruiting	1UG3CA244687-01
clinical_trial	NCT03009201	Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery	June 15, 2021	Active, not recruiting	1UG3CA244687-01
clinical_trial	NCT02691026	A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery	June 23, 2021	Terminated	1UG3CA244687-01
clinical_trial	NCT02834013	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	September 17, 2021	Recruiting	1UG3CA244687-01
clinical_trial	NCT04222413	Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors	September 5, 2021	Recruiting	1UG3CA244687-01
clinical_trial	NCT03880123	Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma	November 27, 2020	Withdrawn
                  
      <!--	1UG3CA244687-01
clinical_trial	NCT00064129	Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer	July 30, 2020	Completed	1U01CA233100-01
clinical_trial	NCT01363206	Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma (GIPI)	March 19, 2020	Completed	1U01CA233100-01
clinical_trial	NCT03799432	Collaborative Organizational Approach to Selecting and Tailoring Implementation Strategies (COAST-IS)	January 8, 2021	Active, not recruiting	1P50CA244431-01
clinical_trial	NCT02343939	Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) (ENTO in AML)	November 15, 2019	Terminated	1U01CA232486-01
clinical_trial	NCT02404220	Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)	January 2, 2020	Terminated	1U01CA232486-01
clinical_trial	NCT03135028	Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults (Japanese AML)	March 6, 2020	Terminated	1U01CA232486-01
clinical_trial	NCT01141126				1U01CA232486-01
clinical_trial	NCT02828358	Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement	August 2, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT03705507	International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia (SeluDex)	January 19, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT00557193	Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	March 25, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT04317092	Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) (TOCIVID-19)	March 3, 2021	Active, not recruiting	1U24CA233032-01
clinical_trial	NCT04315298	Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19	October 1, 2020	Completed	1U24CA233032-01
clinical_trial	NCT02451423	Neoadjuvant Atezolizumab in Localized Bladder Cancer	March 30, 2020	Recruiting	1U01CA233100-01
clinical_trial	NCT02451423	Neoadjuvant Atezolizumab in Localized Bladder Cancer	March 30, 2020	Recruiting	1U01CA244452-01
clinical_trial	NCT02215967	Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma	October 8, 2019	Completed	2P01CA155258-06
clinical_trial	NCT02658929	Study of bb2121 in Multiple Myeloma	December 4, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03274219	Study of bb21217 in Multiple Myeloma	March 18, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03093168	BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma	February 27, 2019	Unknown	2P01CA155258-06
clinical_trial	NCT03338972	Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma	June 10, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03338972	Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma	June 10, 2021	Active, not recruiting	1U01CA247548-01
clinical_trial	NCT02546167	CART-BCMA Cells for Multiple Myeloma	August 4, 2020	Completed	2P01CA155258-06
clinical_trial	NCT03661554	BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma (BCMA CAR-T)	September 10, 2018	Unknown	2P01CA155258-06
clinical_trial	NCT03196414	Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma	May 2, 2019	Recruiting	2P01CA155258-06
clinical_trial	NCT03455972	Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT	May 19, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03716856	Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma	October 8, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03302403	Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors	October 8, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03380039	Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma	October 12, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03430011	Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE)	June 1, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03090659	LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)	September 2, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03548207	A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1)	September 16, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03288493	P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)	September 14, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT02064387	Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916	August 11, 2020	Completed	2P01CA155258-06
clinical_trial	NCT03525678	A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody	November 23, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02514239	Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients	July 22, 2021	Completed	2P01CA155258-06
clinical_trial	NCT03486067	Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma	August 20, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03269136	PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma	July 2, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03489525	MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)	August 5, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03287908	A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma	August 27, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT04184050	A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM	September 10, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03448978	Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma	February 10, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03266692	Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma	March 30, 2020	Terminated	2P01CA155258-06
clinical_trial	NCT03651128	Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)	August 11, 2020	Recruiting	2P01CA155258-06
clinical_trial	NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)	September 17, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT04126200	Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)	July 20, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT04246047	Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)	July 22, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03502577	BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma	August 2, 2021	Suspended
                  
      <!--	2P01CA155258-06
clinical_trial	NCT03502577	BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma	August 2, 2021	Suspended
                  
      <!--	1U01CA247548-01
clinical_trial	NCT04093596	Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL)	June 24, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03940833	Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM	May 7, 2019	Recruiting	2P01CA155258-06
clinical_trial	NCT03848845	Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 4)	May 20, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03544281	To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 6)	May 19, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03715478	Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex	August 10, 2020	Recruiting	2P01CA155258-06
clinical_trial	NCT04091126	Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (DREAMM 9)	July 20, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT04196491	A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)	May 18, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03225105	M3541 in Combination With Radiotherapy in Subjects With Solid Tumors	September 14, 2020	Completed	1U54CA244719-01
clinical_trial	NCT02588105	Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (AToM)	August 18, 2021	Active, not recruiting	1U54CA244719-01
clinical_trial	NCT02494583	Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)	March 10, 2021	Active, not recruiting	1U54CA244719-01
clinical_trial	NCT03189719	First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)	July 6, 2021	Active, not recruiting	1U54CA244719-01
clinical_trial	NCT01120288	A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases	July 5, 2018	Completed	1U01DE029255-01
clinical_trial	NCT00466583	Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma	July 7, 2011	Completed	1U01DE029255-01
clinical_trial	NCT00400946	Treatment of Acute Lymphoblastic Leukemia in Children	November 20, 2019	Completed	3R00CA181500-04S1
clinical_trial	NCT00408005	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma	May 25, 2021	Active, not recruiting	3R00CA181500-04S1
clinical_trial	NCT01191060	Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)	April 18, 2019	Completed	2P01CA155258-06
clinical_trial	NCT03958383	IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma	November 27, 2020	Recruiting	1U01CA233102-01
clinical_trial	NCT03958383	IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma	November 27, 2020	Recruiting	1U54CA232568-01
clinical_trial	NCT01415882	Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib	April 8, 2021	Recruiting	1U54CA224018-01
clinical_trial	NCT04358276	Technology-Enabled Activation of Skin Cancer Screening for Stem Cell Transplant Survivors and Their Primary Care Providers, TEACH Study	February 16, 2021	Recruiting	1R01CA249460-01
clinical_trial	NCT03278340	Using Technology to Scale-Up an Occupational Sun Protection Policy Program (SSW-T)	July 9, 2021	Enrolling by invitation	1R01CA210259-01A1
clinical_trial	NCT02181413	A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant	March 9, 2021	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT00114101	Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant	June 23, 2021	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT02550327	Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer	June 22, 2021	Completed	1U54CA224083-01
clinical_trial	NCT01560923	Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer	April 3, 2020	Completed	1U01CA224151-01
clinical_trial	NCT02073123	Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma	June 5, 2020	Completed	1U01CA224151-01
clinical_trial	NCT02835729	A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia	June 4, 2020	Completed	1U01CA224151-01
clinical_trial	NCT02052648	Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors	May 28, 2020	Completed	1U01CA224151-01
clinical_trial	NCT03301636	A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma (NLG2107)	June 5, 2020	Terminated	1U01CA224151-01
clinical_trial	NCT02502648				1U01CA224151-01
clinical_trial	NCT02728102	Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)	September 9, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT04514341	Implementing a Multilevel Intervention to Accelerate Colorectal Cancer Screening and Follow-up	August 14, 2020	Not yet recruiting	1UG3CA233229-01
clinical_trial	NCT02840058	Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1 (ITHER)	August 2, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT04302675	Adapting Motivational Interviewing for Maternal Immunizations (MI4MI) (MI4MI)	July 26, 2021	Active, not recruiting	1P50CA244688-01
clinical_trial	NCT03224507	Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma (MASTER)	April 21, 2020	Recruiting	2P01CA155258-06
clinical_trial	NCT04071457	S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)	February 24, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT04513639	The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study	June 18, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03683277	IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic (IFM2014-01)	September 25, 2018	Not yet recruiting	2P01CA155258-06
clinical_trial	NCT03077477	Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers	June 14, 2018	Withdrawn
                  
      <!--	1U01CA232488-01
clinical_trial	NCT02369874	Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)	February 10, 2021	Completed	1U01DE029188-01
clinical_trial	NCT00404339	Vaccine Therapy in Treating Patients With Head and Neck Cancer	April 18, 2016	Completed	1U01DE029188-01
clinical_trial	NCT00257738	0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck	October 17, 2019	Completed	1U01DE029188-01
clinical_trial	NCT02426892	Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors	February 17, 2020	Active, not recruiting	1U01DE029188-01
clinical_trial	NCT01147991	Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer	February 28, 2012	Completed	1U01DE029188-01
clinical_trial	NCT03821272	A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients	May 13, 2021	Recruiting	1U01DE029188-01
clinical_trial	NCT02002182	ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer	July 2, 2021	Active, not recruiting	1U01DE029188-01
clinical_trial	NCT02865135	Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer	September 9, 2021	Active, not recruiting	1U01DE029188-01
clinical_trial	NCT03260023	Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers	June 29, 2021	Recruiting	1U01DE029188-01
clinical_trial	NCT03418480	HPV Anti-CD40 RNA Vaccine (HARE-40)	May 6, 2021	Active, not recruiting	1U01DE029188-01
clinical_trial	NCT04369937	HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for &quot;Intermediate Risk&quot; HPV-16-associated Head and Neck Squamous Cell Carcinoma	October 22, 2020	Recruiting	1U01DE029188-01
clinical_trial	NCT02544880	PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC	June 15, 2021	Completed	1U01DE029188-01
clinical_trial	NCT04247282	Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection	June 9, 2021	Suspended
                  
      <!--	1U01DE029188-01
clinical_trial	NCT02999646	Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC	March 30, 2021	Recruiting	1U01DE029188-01
clinical_trial	NCT03568058	Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers	December 9, 2020	Active, not recruiting	1U01DE029188-01
clinical_trial	NCT04266730	Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC)	July 8, 2021	Not yet recruiting	1U01DE029188-01
clinical_trial	NCT03689192	Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors	February 12, 2020	Recruiting	1U01DE029188-01
clinical_trial	NCT00019110	Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer	April 29, 2015	Completed	1U01DE029188-01
clinical_trial	NCT00019331	Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors	June 20, 2013	Completed	1U01DE029188-01
clinical_trial	NCT00021424	Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer	April 30, 2015	Completed	1U01DE029188-01
clinical_trial	NCT00027534	Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer	September 8, 2014	Completed	1U01DE029188-01
clinical_trial	NCT01462838	Immune Therapy of HPV-induced Cancers	June 23, 2015	Completed	1U01DE029188-01
clinical_trial	NCT01998542	Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (HNC)	January 23, 2020	Completed	1U01DE029188-01
clinical_trial	NCT02163057	Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma	January 22, 2021	Completed	1U01DE029188-01
clinical_trial	NCT02291055	Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer	February 19, 2020	Active, not recruiting	1U01DE029188-01
clinical_trial	NCT02526316	Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers (VICORYX-2)	July 2, 2017	Completed	1U01DE029188-01
clinical_trial	NCT03162224	Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer	April 27, 2021	Completed	1U01DE029188-01
clinical_trial	NCT03701295	Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement	September 9, 2021	Completed	5R01CA176745-09
clinical_trial	NCT03724084	Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement	September 8, 2021	Active, not recruiting	5R01CA176745-09
clinical_trial	NCT04065399	A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)	May 6, 2021	Recruiting	5R01CA176745-09
clinical_trial	NCT04067336	First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia	August 24, 2021	Recruiting	5R01CA176745-09
clinical_trial	NCT02698176	A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)	January 27, 2021	Terminated	5R01CA176745-09
clinical_trial	NCT03068351	Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma	February 7, 2020	Completed	5R01CA176745-09
clinical_trial	NCT03292172	A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer	November 6, 2020	Terminated	5R01CA176745-09
clinical_trial	NCT03255096	A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6	January 28, 2021	Completed	5R01CA176745-09
clinical_trial	NCT04320238	Experimental Trial of rhIFN&#945; Nasal Drops to Prevent 2019-nCOV in Medical Staff	March 31, 2020	Recruiting	1U01CA224348-01
clinical_trial	NCT03019003	Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients	December 1, 2020	Recruiting	1U01DE029188-01
clinical_trial	NCT03525795	ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors	January 11, 2021	Completed	1U01DE029188-01
clinical_trial	NCT03854474	Tazemetostat and Pembrolizumab in Treating Patients With Locally Advanced or Metastatic Urothelial Carcinoma	September 16, 2021	Recruiting	1U01DE029188-01
clinical_trial	NCT01693562	A Phase 1/2 Study to Evaluate MEDI4736	May 13, 2021	Completed	1U01CA233100-01
clinical_trial	NCT03125239	Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia	June 30, 2020	Completed	3R01CA204396-02S1
clinical_trial	NCT01495598	Pomalidomide for Kaposi Sarcoma in People With or Without HIV	September 5, 2021	Active, not recruiting	2UM1CA154967-07
clinical_trial	NCT02659930	Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma	September 5, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT00006518	Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer	September 14, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT00092222	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity	September 14, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT01419561	History of the KSHV Inflammatory Cytokine Syndrome (KICS)	September 14, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT00983424	Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer	September 16, 2013	Completed	3U54CA224065-01S1
clinical_trial	NCT02188264	Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer	April 2, 2021	Active, not recruiting	3U54CA224065-01S1
clinical_trial	NCT00003950	Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer	March 7, 2014	Completed	3U54CA224065-01S1
clinical_trial	NCT01391143	Safety Study of MGA271 in Refractory Cancer	January 10, 2020	Completed	1U54CA224079-01
clinical_trial	NCT04129320	Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck	October 14, 2020	Withdrawn
                  
      <!--	1U54CA224079-01
clinical_trial	NCT01942837	Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling	January 12, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT01924689	Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies	September 9, 2019	Completed	1UG3CA244687-01
clinical_trial	NCT02807805	Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer	March 19, 2021	Recruiting	1U54CA233306-01
clinical_trial	NCT03111992	Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma	September 9, 2020	Completed	1U01CA244291-01
clinical_trial	NCT02703623	Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer	November 12, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02703623	Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer	November 12, 2020	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT01688492	Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer	September 10, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT01688492	Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer	September 10, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT04388852	DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers	June 29, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT04388852	DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers	June 29, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT02787005	Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)	August 23, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02787005	Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)	August 23, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03834493	Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)	September 16, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03834493	Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)	September 16, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT02312557	Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide	May 17, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02312557	Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide	May 17, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03770455	Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC	October 19, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03770455	Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC	October 19, 2020	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03338790	An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CheckMate 9KD)	August 30, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03338790	An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CheckMate 9KD)	August 30, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT02861573	Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)	September 16, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT02861573	Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)	September 16, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03658447	PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) (PRINCE)	December 23, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03658447	PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) (PRINCE)	December 23, 2020	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03093428	Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC	July 28, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03093428	Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC	July 28, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03834506	Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-na&#239;ve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)	June 9, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03834506	Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-na&#239;ve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)	June 9, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03248570	Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects	May 26, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03248570	Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects	May 26, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT02998567	Combination Study of Guadecitabine and Pembrolizumab. (HyPeR)	November 17, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02998567	Combination Study of Guadecitabine and Pembrolizumab. (HyPeR)	November 17, 2020	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03582475	Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate	July 14, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03582475	Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate	July 14, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03572478	Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer	March 9, 2021	Terminated	1U01CA233100-01
clinical_trial	NCT03572478	Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer	March 9, 2021	Terminated	1U01CA244452-01
clinical_trial	NCT03834519	Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010)	September 16, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03834519	Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010)	September 16, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT02484404	Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers	September 13, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT02484404	Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers	September 13, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03330405	Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors	September 8, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03330405	Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors	September 8, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT04446117	Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)	September 17, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT04446117	Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)	September 17, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03849469	A Study of XmAb&#174;22841 Monotherapy &amp; in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)	August 18, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03849469	A Study of XmAb&#174;22841 Monotherapy &amp; in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)	August 18, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03406858	Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer	March 1, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03406858	Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer	March 1, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03217747	Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies	October 30, 2020	Recruiting	1U01CA233100-01
clinical_trial	NCT03217747	Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies	October 30, 2020	Recruiting	1U01CA244452-01
clinical_trial	NCT03821246	Atezolizumab With or Without Tocilizumab in Treating Men With Prostate Cancer Before Radical Prostatectomy	November 12, 2020	Recruiting	1U01CA233100-01
clinical_trial	NCT03821246	Atezolizumab With or Without Tocilizumab in Treating Men With Prostate Cancer Before Radical Prostatectomy	November 12, 2020	Recruiting	1U01CA244452-01
clinical_trial	NCT03473925	Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)	July 2, 2021	Completed	1U01CA233100-01
clinical_trial	NCT03473925	Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)	July 2, 2021	Completed	1U01CA244452-01
clinical_trial	NCT04020094	Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer (AtezoVax)	July 21, 2021	Withdrawn
                  
      <!--	1U01CA233100-01
clinical_trial	NCT04020094	Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer (AtezoVax)	July 21, 2021	Withdrawn
                  
      <!--	1U01CA244452-01
clinical_trial	NCT03835533	Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)	August 3, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03835533	Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)	August 3, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT04090775	A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma	October 11, 2019	Recruiting	1U01CA233100-01
clinical_trial	NCT04090775	A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma	October 11, 2019	Recruiting	1U01CA244452-01
clinical_trial	NCT03518606	Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE)	September 16, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03518606	Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE)	September 16, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03532217	Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer	September 17, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03532217	Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer	September 17, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03204812	Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer	April 15, 2021	Completed	1U01CA233100-01
clinical_trial	NCT03204812	Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer	April 15, 2021	Completed	1U01CA244452-01
clinical_trial	NCT02985957	Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)	April 23, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT02985957	Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)	April 23, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03879122	A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer	August 12, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03879122	A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer	August 12, 2020	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03866382	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors	September 16, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03866382	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors	September 16, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03454451	CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers	July 27, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03454451	CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers	July 27, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT02655822	Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers	August 30, 2021	Completed	1U01CA233100-01
clinical_trial	NCT02655822	Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers	August 30, 2021	Completed	1U01CA244452-01
clinical_trial	NCT04089553	An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer	August 3, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT04089553	An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer	August 3, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT02740985	A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies	July 30, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02740985	A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies	July 30, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT04381832	Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)	July 28, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT04381832	Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)	July 28, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03792841	Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC	June 7, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03792841	Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC	June 7, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT04631601	Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)	August 23, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT04631601	Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)	August 23, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03972657	Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer	July 12, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03972657	Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer	July 12, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT04702737	A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer	September 10, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT04702737	A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer	September 10, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT04221542	Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer	September 2, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT04221542	Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer	September 2, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03577028	Study of HPN424 in Patients With Advanced Prostate Cancer	October 5, 2020	Recruiting	1U01CA233100-01
clinical_trial	NCT03577028	Study of HPN424 in Patients With Advanced Prostate Cancer	October 5, 2020	Recruiting	1U01CA244452-01
clinical_trial	NCT04397276	A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors	September 10, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT04397276	A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors	September 10, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	January 14, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	January 14, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03873805	PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer	March 10, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03873805	PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer	March 10, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03753243	Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer	September 23, 2020	Recruiting	1U01CA233100-01
clinical_trial	NCT03753243	Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer	September 23, 2020	Recruiting	1U01CA244452-01
clinical_trial	NCT03810105	A Study of Olaparib and Durvalumab in Prostate Cancer	September 16, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03810105	A Study of Olaparib and Durvalumab in Prostate Cancer	September 16, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03016312	A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen (IMbassador250)	August 19, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03016312	A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen (IMbassador250)	August 19, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT04131413	HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia	July 6, 2021	Recruiting	1U01CA233056-01
clinical_trial	NCT04131413	HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia	July 6, 2021	Recruiting	1U01CA233097-01
clinical_trial	NCT01440088	A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma	June 2, 2016	Completed	3R01CA187532-03S1
clinical_trial	NCT01746979	Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (MAESTRO)	December 2, 2017	Completed	3R01CA187532-03S1
clinical_trial	NCT03747484	Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer	July 8, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT02014909	A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors	July 24, 2017	Completed	1U01DE028227-01
clinical_trial	NCT03254927	A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma	April 28, 2021	Completed	1U01DE028227-01
clinical_trial	NCT03684889	CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma	February 10, 2021	Active, not recruiting	1U01CA247548-01
clinical_trial	NCT01865617	Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia	July 20, 2021	Completed	1U01CA247548-01
clinical_trial	NCT02706392	Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies	July 8, 2021	Recruiting	1U01CA247548-01
clinical_trial	NCT03103971	huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia	September 10, 2021	Recruiting	1U01CA247548-01
clinical_trial	NCT02706405	JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	July 16, 2021	Active, not recruiting	1U01CA247548-01
clinical_trial	NCT02631044	Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)	June 21, 2021	Recruiting	1U01CA247548-01
clinical_trial	NCT03277729	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	July 13, 2021	Recruiting	1U01CA247548-01
clinical_trial	NCT03105336	A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)	August 5, 2021	Active, not recruiting	1U01CA247548-01
clinical_trial	NCT02614066	A Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) (ZUMA-3)	June 28, 2021	Active, not recruiting	1U01CA247548-01
clinical_trial	NCT03331198	Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)	May 7, 2021	Recruiting	1U01CA247548-01
clinical_trial	NCT03575351	A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM)	June 10, 2021	Active, not recruiting	1U01CA247548-01
clinical_trial	NCT02504372	Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) (PEARLS)	July 17, 2020	Active, not recruiting	1U01CA233102-01
clinical_trial	NCT02998528	A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)	August 26, 2020	Active, not recruiting	1U01CA233102-01
clinical_trial	NCT04025879	A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer	August 25, 2021	Recruiting	1U01CA233102-01
clinical_trial	NCT04214262	Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer	September 14, 2021	Recruiting	1U01CA233102-01
clinical_trial	NCT02884102	MMRF Molecular Profiling Protocol	March 19, 2019	Recruiting	1U2CCA233303-01
clinical_trial	NCT01239134	Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)	August 14, 2019	Completed	1U01CA224348-01
clinical_trial	NCT01239134	Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)	August 14, 2019	Completed	1U2CCA233262-01
clinical_trial	NCT04021043	BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers	January 14, 2021	Recruiting	1U01CA224348-01
clinical_trial	NCT04021043	BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers	January 14, 2021	Recruiting	1U2CCA233262-01
clinical_trial	NCT02740270	Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas	February 21, 2021	Completed	1U01CA224348-01
clinical_trial	NCT02740270	Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas	February 21, 2021	Completed	1U2CCA233262-01
clinical_trial	NCT02628574	Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab	October 26, 2020	Completed	1U01CA224348-01
clinical_trial	NCT02628574	Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab	October 26, 2020	Completed	1U2CCA233262-01
clinical_trial	NCT02598960	An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.	December 21, 2020	Completed	1U01CA224348-01
clinical_trial	NCT02598960	An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.	December 21, 2020	Completed	1U2CCA233262-01
clinical_trial	NCT04225039	Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma	February 5, 2021	Recruiting	1U01CA224348-01
clinical_trial	NCT04225039	Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma	February 5, 2021	Recruiting	1U2CCA233262-01
clinical_trial	NCT01804465	Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer	August 18, 2021	Completed	1U01CA233100-01
clinical_trial	NCT01804465	Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer	August 18, 2021	Completed	1U01CA244452-01
clinical_trial	NCT01626495	Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)	March 23, 2020	Completed	1U01CA232361-01A1
clinical_trial	NCT04427527	Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia (ACCSIS)	May 3, 2021	Recruiting	1UG3CA233282-01
clinical_trial	NCT01383538	FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma	August 8, 2017	Completed	1U54CA224083-01
clinical_trial	NCT01195415	Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer	August 7, 2017	Completed	1U54CA224083-01
clinical_trial	NCT01064622	Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer	August 14, 2015	Completed	1U54CA224083-01
clinical_trial	NCT01088815	Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas	April 26, 2019	Completed	1U54CA224083-01
clinical_trial	NCT01487785	Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients	December 19, 2020	Completed	1U54CA224083-01
clinical_trial	NCT02358161	Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (MATRIX)	January 9, 2020	Completed	1U54CA224083-01
clinical_trial	NCT01373164	A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer	May 16, 2018	Completed	1U54CA224083-01
clinical_trial	NCT03941093	Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Locally Advanced Pancreatic Cancer	September 17, 2021	Recruiting	1U54CA224083-01
clinical_trial	NCT04054362	Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PINBALL)	December 16, 2019	Unknown	1U54CA224083-01
clinical_trial	NCT04524702	Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer	February 21, 2021	Recruiting	1U54CA224083-01
clinical_trial	NCT03883919	Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy	May 18, 2021	Active, not recruiting	1U54CA224083-01
clinical_trial	NCT03331562	A SU2C Catalyst&#174; Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer	October 8, 2020	Completed	1U54CA224083-01
clinical_trial	NCT03307148	Stromal TARgeting for PAncreatic Cancer (STAR_PAC) (STAR_PAC)	January 22, 2020	Completed	1U54CA224083-01
clinical_trial	NCT02715804	A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma	July 14, 2020	Terminated	1U54CA224083-01
clinical_trial	NCT01959139	S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer	January 5, 2021	Active, not recruiting	1U54CA224083-01
clinical_trial	NCT01472198	A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma	March 10, 2015	Completed	1U54CA224083-01
clinical_trial	NCT03985852	Broadening the Reach, Impact, and Delivery of Genetic Services (BRIDGE)	August 27, 2021	Enrolling by invitation	1U01CA232826-01
clinical_trial	NCT02588443	Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma	April 16, 2019	Completed	1U01CA224193-01
clinical_trial	NCT02453594	Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)	April 19, 2021	Active, not recruiting	1U54CA232568-01
clinical_trial	NCT02992964	Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers	February 15, 2021	Active, not recruiting	1U54CA232568-01
clinical_trial	NCT03241940	Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies	August 17, 2021	Recruiting	1U54CA232568-01
clinical_trial	NCT03289455	CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)	February 1, 2021	Completed	1U54CA232568-01
clinical_trial	NCT04365257	Prazosin to Prevent COVID-19 (PREVENT-COVID Trial) (PREVENT)	June 9, 2021	Recruiting	1U01CA247576-01
clinical_trial	NCT02306954	Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer	March 3, 2020	Recruiting	1U54CA232568-01
clinical_trial	NCT03607617	ASCEND: ApproacheS to CHC ImplEmeNtation of SDH Data Collection and Action (ASCEND)	June 15, 2021	Active, not recruiting	1P50CA244289-01
clinical_trial	NCT00546156	Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer	May 18, 2021	Completed	1U01CA224348-01
clinical_trial	NCT02484443	Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma	August 5, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT03233854	CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies	August 17, 2021	Recruiting	1U54CA232568-01
clinical_trial	NCT04088890	Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies	August 3, 2021	Recruiting	1U54CA232568-01
clinical_trial	NCT04131062	Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants	January 22, 2021		1R01CA211723-01A1
clinical_trial	NCT03698162	Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases	April 5, 2021		1R33CA225400-01
clinical_trial	NCT01946789	A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors	April 17, 2019		2UM1CA154967-07
clinical_trial	NCT01961115	Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma	June 8, 2018	Completed	2UM1CA154967-07
clinical_trial	NCT04751383	Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma	August 30, 2021		2UM1CA154967-07
clinical_trial	NCT04500548	Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study	August 26, 2021		2UM1CA154967-07
clinical_trial	NCT03513952	Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma	September 14, 2021		2UM1CA154967-07
clinical_trial	NCT02243579	Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome	September 20, 2019	Completed	2UM1CA154967-07
clinical_trial	NCT04410302	Patient-Derived Xenografts to Reduce Cancer Health Disparities	July 13, 2021		1U54CA233306-01
clinical_trial	NCT04406714	Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE)	May 12, 2021		1UG3CA233251-01
clinical_trial	NCT03892967	Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) Pragmatic Clinical Trial	August 13, 2021		1UM1CA233033-01
clinical_trial	NCT03988543	Bilingual Electronic Symptom Management Program Across Multi-site, Comprehensive Cancer Center	March 3, 2021		1UM1CA233035-01
clinical_trial	NCT03850912	Symptom Management Implementation of Patient Reported Outcomes in Oncology	September 16, 2020		1UM1CA233080-01
clinical_trial	NCT04199026	Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma	March 6, 2020		3R01CA180279-05S1
clinical_trial	NCT03538938	Improving Quitline Support Study	May 17, 2021		5R01CA218156-02
clinical_trial	NCT04314284	Patient-Centered Intervention to Reduce Cancer Patients&apos; Financial Toxicity	January 14, 2021		1P50CA244431-01
clinical_trial	NCT04585919	Paired Promotion of Colorectal Cancer and Social Determinants of Health Screening	April 1, 2021		1P50CA244433-01
clinical_trial	NCT05021133	Tele-Navigation of Lung Cancer Screening (Tele-Navi LCS)	August 31, 2021	Not yet recruiting	1P50CA244693-01
clinical_trial	NCT04337203	Shared Healthcare Actions and Reflections Electronic Systems in Survivorship	June 18, 2021		1P50CA244693-01
clinical_trial	NCT04746794	Early Detection of GEnetic Risk (EDGE)	February 10, 2021		1U01CA232795-01A1
clinical_trial	NCT04323774	Intervention For AYAS With Cancer Risk Syndromes	April 13, 2021		1U01CA243688-01
clinical_trial	NCT04939597	A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor	June 25, 2021		1U01CA246568-01
clinical_trial	NCT04789720	Using Information Technology to Improve Outcomes for Children Living With Cancer	June 18, 2021		1U01CA246612-01
clinical_trial	NCT04089358	Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study	August 25, 2021		1U01CA246665-01
clinical_trial	NCT04941300	ColoRectal Cancer Screening for Southern California Community Health Centers	July 19, 2021		1UG3CA233314-01A1
clinical_trial	NCT04890054	Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC	July 15, 2021		1UG3CA244298-01
clinical_trial	NCT04745754	The Engaging Primary Care in Cancer Survivorship (EPICS) Study	August 4, 2021		1R01CA249419-01
clinical_trial	NCT05006482	Geriatric Evaluation and Management With Survivorship Health Education (GEMS) for Older Survivors of Cancer	August 31, 2021		1R01CA249467-01
clinical_trial	NCT04428905	Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer	February 16, 2021		1R01CA249501-01
clinical_trial	NCT04494945	Identifying and Caring for Individuals With Inherited Cancer Syndrome	June 2, 2021		1U01CA232819-01A1
